Clinical Trial Update: Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating lenalidomide and high-dose melphalan followed by autologous stem cell transplant in multiple myeloma has completed with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous Stem Cell Transplant
• Lenalidomide (lenalidomide)
• high-dose melphalan (melphalan)

Snippet

Sponsor: Attaya Suvannasankha | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-10-22